Lung SABR: What is standard and what should remain investigational for now?
Professor Suresh Senan, Amsterdam University Medical Center, Netherlands
Suresh Senan is Professor of clinical experimental radiotherapy at the Amsterdam University Medical Centers in The Netherlands. After training in general internal medicine at the National University of Singapore, he completed training in clinical oncology at the Beatson in Glasgow. Since 1994, he has been working in The Netherlands, and his recent research has focused on immune checkpoint inhibitors for lung malignancies, Magnetic Resonance-guided adaptive radiotherapy and comparative effectiveness research. He is a faculty member at the European Society for Medical Oncology, and an active member of the International Association for the Study of Lung Cancer.
Technical advances in SABR for patients with liver cancers
Dr Michael Velec, PhD, Princess Margaret Cancer Centre in Toronto, Canada
Dr. Michael Velec is an MRT(T) appointed as a Radiation Therapist–Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, where he focuses on translating novel radiotherapy techniques and strategies into the clinic setting. He is an Assistant Professor in Radiation Oncology at the University of Toronto, and Affiliate Faculty at the Techna Institute for the Advancement of Technology for Health. Michael completed his PhD in medical sciences at the University of Toronto in 2014, and a postdoctoral fellowship at the Techna Institute in 2016.
Dr. Velec has current research interests in deformable image registration and dose accumulation for the applications of adaptive radiation therapy and understanding dose-response relationships for tumor control and normal tissue toxicities. Ongoing projects also include the development of new models of care delivered by Radiation Therapists that simultaneously enables precision medicine and person-centered care. Michael is also engaged in teaching both trainees and practicing health professionals in radiation medicine.